{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:21:16Z","timestamp":1767838876169,"version":"3.49.0"},"reference-count":10,"publisher":"Centers for Disease Control MMWR Office","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7230a4","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:00:10Z","timestamp":1690473610000},"page":"827-832","source":"Crossref","is-referenced-by-count":4,"title":["Demographic Disparities in Mpox Vaccination Series Completion, by Route of Vaccine Administration \u2014 California, August 9, 2022\u2013March 31, 2023"],"prefix":"10.15585","volume":"72","author":[{"given":"Tarek","family":"Salih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josh","family":"Vance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Quint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Meza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"McNitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Webster U.","family":"Lincoln","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6224","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"key-10.15585\/mmwr.mm7230a4-202307271155-R1","unstructured":"Administration for Strategic Preparedness and Response. JYNNEOS vaccine distribution by jurisdiction: mpox national vaccine strategy. Washington, DC: US Department of Health and Human Services, Administration for Strategic Preparedness and Response; 2022. https:\/\/aspr.hhs.gov\/SNS\/Pages\/JYNNEOS-Distribution.aspx"},{"key":"key-10.15585\/mmwr.mm7230a4-202307271155-R2","unstructured":"CDC. Mpox: technical report 4, United States, 2022. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/www.cdc.gov\/poxvirus\/mpox\/cases-data\/technical-report\/report-4.html"},{"key":"key-10.15585\/mmwr.mm7230a4-202307271155-R3","unstructured":"Food and Drug Administration. Monkeypox update: FDA authorizes emergency use of JYNNEOS vaccine to increase vaccine supply [Press release]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/monkeypox-update-fda-authorizes-emergency-use-jynneos-vaccine-increase-vaccine-supply"},{"key":"key-10.15585\/mmwr.mm7230a4-202307271155-R4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4161\/hv.3.4.4140","article-title":"Extensive keloid formation and progression after each vaccination.","volume":"3","author":"Coop","year":"2007","journal-title":"Hum Vaccin"},{"key":"key-10.15585\/mmwr.mm7230a4-202307271155-R5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/0033354919849882","article-title":"California Healthy Places Index: frames matter.","volume":"134","author":"Maizlish","year":"2019","journal-title":"Public Health Rep"},{"key":"key-10.15585\/mmwr.mm7230a4-202307271155-R6","doi-asserted-by":"publisher","first-page":"101868","DOI":"10.1016\/j.tmaid.2020.101868","article-title":"Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination\u2014a systematic review and meta-analysis.","volume":"37","author":"Schnyder","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"key-10.15585\/mmwr.mm7230a4-202307271155-R7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.15585\/mmwr.mm7220a3","article-title":"Estimated effectiveness of JYNNEOS vaccine in preventing mpox: a multijurisdictional case-control study\u2014United States, August 19, 2022\u2013March 31, 2023.","volume":"72","author":"Dalton","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7230a4-202307271155-R8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.15585\/mmwr.mm7149a5","article-title":"Reduced risk for mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons\u201443 U.S. jurisdictions, July 31\u2013October 1, 2022.","volume":"71","author":"Payne","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7230a4-202307271155-R9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMc2215846","article-title":"Erythema and induration after mpox (JYNNEOS) vaccination revisited.","volume":"388","author":"Frey","year":"2023","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm7230a4-202307271155-R10","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.15585\/mmwr.mm7149a4","article-title":"Safety monitoring of JYNNEOS vaccine during the 2022 mpox outbreak\u2014United States, May 22\u2013October 21, 2022.","volume":"71","author":"Duffy","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:00:16Z","timestamp":1690473616000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7230a4.htm?s_cid=mm7230a4_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":10,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2023,7,28]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7230a4","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,28]]},"published":{"date-parts":[[2023,7,28]]}}}